CereVasc Receives FDA IDE Approval to Evaluate eShunt System in Alzheimer's Disease
CereVasc has received an FDA investigational device exemption to evaluate its eShunt System in patients with Alzheimer's disease, extending the device program beyond hydrocephalus.